InsidersTradesSigma
Total declarations
Companies
▲ Purchases (10 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by Pauls Matthew, Director. Insider active across 3 companies, notably Pelthos Therapeutics Inc.. Cumulatively, 16 reports have been logged. Total volume traded: €108k. The latest transaction was filed on 2 July 2025 — Attribution. Regulator: SEC (Form 4). All data is openly available.
Declarations16 total
025,478 shares0
Common Stock
SEC:0001919246-26-000042·
025,478 shares0
Common Stock
SEC:0001919246-26-000042:0·
€68,23362,318 shares@ €1.09490.0055% mcap50.4% of flow
Common Stock
SEC:0001209191-22-000131:0·
€68,23362,318 shares@ €1.09490.0066% mcap62.7% of flow
Common Stock
SEC:0001209191-22-000131·
0400,000 shares0
Common Stock
SEC:0001209191-21-069586·
0400,000 shares0
Common Stock
SEC:0001209191-21-069586:0·
€6,1096,500 shares@ €0.93990.0006% mcap5.6% of flow
Common Stock
SEC:0001209191-21-068494·
Ideal exit: 4 Sept 2022 (T+270)
€6,1096,500 shares@ €0.93990.0005% mcap4.5% of flow
Common Stock
SEC:0001209191-21-068494:0·
Ideal exit: 4 Sept 2022 (T+270)
€9,67710,000 shares@ €0.96770.0009% mcap8.9% of flow
Common Stock
SEC:0001209191-21-067432·
Ideal exit: 29 Aug 2022 (T+270)
€9,67710,000 shares@ €0.96770.0008% mcap7.1% of flow
Common Stock
SEC:0001209191-21-067432:0·
Ideal exit: 29 Aug 2022 (T+270)
€9,71610,000 shares@ €0.97160.0009% mcap8.9% of flow
Common Stock
SEC:0001209191-21-066036·
Ideal exit: 15 Aug 2022 (T+270)
€9,71610,000 shares@ €0.97160.0008% mcap7.2% of flow
Common Stock
SEC:0001209191-21-066036:0·
Ideal exit: 15 Aug 2022 (T+270)
€15,11615,000 shares@ €1.00770.0015% mcap13.9% of flow
Common Stock
SEC:0001209191-21-052200·
Ideal exit: 14 May 2022 (T+270)
€15,11615,000 shares@ €1.00770.0012% mcap11.2% of flow
Common Stock
SEC:0001209191-21-052200:0·
Ideal exit: 14 May 2022 (T+270)
€13,33110,000 shares@ €1.3331100.0% of flow
Common Stock
SEC:0001209191-21-035163·
Ideal exit: 15 Feb 2022 (T+270)
€13,33110,000 shares@ €1.33310.0011% mcap9.8% of flow
Common Stock
SEC:0001209191-21-035163:0·
Ideal exit: 15 Feb 2022 (T+270)
16 of 16 declarations
About Pauls Matthew
Matthew Pauls is a director at Pelthos Therapeutics Inc.
